AVALO THERAPEUTICS, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
AVALO THERAPEUTICS, INC. (AVTX) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $1.56 million as of 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2021-03-08
- 2020-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.56M.
- 2019-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.32M.
- 2018-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.32M.
- 2017-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $3.23M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2020-12-31 | $1.56M 10-K · filed 2021-03-08 |
| 2019-12-31 | $1.32M 10-K · filed 2020-03-11 |
| 2018-12-31 | $4.32M 10-K · filed 2019-03-18 |
| 2017-12-31 | $3.23M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |